Literature DB >> 2157770

Simultaneous vaccination for hepatitis A and B.

B Flehmig1, U Heinricy, M Pfisterer.   

Abstract

Seronegative volunteers (15) were vaccinated at three 1-month intervals with a combined hepatitis A and B vaccine. The vaccine contained a killed hepatitis A vaccine made from hepatitis A virus (HAV) propagated in diploid human fibroblast cell cultures and hepatitis B surface antigen (HBsAg) produced in yeast. After only one injection, all volunteers developed neutralizing antibodies for HAV with antibody titers comparable to those found after gamma globulin administration. Compared with the antibody titers in sera of volunteers vaccinated with HAV vaccine alone, the antibody titers against HAV were significantly higher in the sera of the volunteers simultaneously vaccinated against hepatitis B virus (HBV) after three vaccinations. Of 15 volunteers, 14 seroconverted against HBV after three injections. In 11 volunteers tested 48 weeks after vaccination, antibody titers against HAV and HBV remained high.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157770     DOI: 10.1093/infdis/161.5.865

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  New vaccines against hepatitis A enter the market--but who should be vaccinated?

Authors:  S Iwarson
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

2.  Silencing of hepatitis A virus infection by small interfering RNAs.

Authors:  Yuri Kusov; Tatsuo Kanda; Ann Palmenberg; Jean-Yves Sgro; Verena Gauss-Müller
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 3.  Innate and adaptive immune responses against picornaviruses and their counteractions: An overview.

Authors:  Andreas Dotzauer; Leena Kraemer
Journal:  World J Virol       Date:  2012-06-12

Review 4.  Clinical development of a new inactivated hepatitis A vaccine.

Authors:  E Vidor; B Fritzell; S Plotkin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

5.  Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth.

Authors:  N Linder; R Handsher; B German; L Sirota; M Bachman; S Zinger; E Mendelson; A Barzilai
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-07       Impact factor: 5.747

Review 6.  Safety and effectiveness of the new inactivated hepatitis A virus vaccine.

Authors:  J Furesz; D W Scheifele; L Palkonyay
Journal:  CMAJ       Date:  1995-02-01       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.